Skip to content

Been withdrawn with the reason of the original applicants cannot provide the individual participants data for reviewing Safety and validity evaluation of HIV immune gene CCR5 gene editing in human embryos

Evaluation of the safety and efficacy of gene editing with human embryo CCR5 gene

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019378
Enrollment
Unknown
Registered
2018-11-08
Start date
2017-03-07
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Interventions

Case series:CCR5 gene editing

Sponsors

South University of Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
22 Years to 38 Years

Inclusion criteria

Inclusion criteria: 1. Married couple living in the People's Republic of China with HIV seropositivity (female negative, male positive); 2. Men and women 22–38 years old; 3. Males are clinically stable, failing to detect viral load of 250; at least in the past 12 months with a history of continuous antiretroviral therapy; 4. Clinically confirmed to meet the medical guidelines for IVF therapy; 5. Fully informed consent of the couple to understand the purpose, risks and benefits of the trial; 6. Both subjects are willing to commit to using preventive contraception or maintaining abstinence for at least two months before egg collection and within one month after birth.

Exclusion criteria

Exclusion criteria: 1. The viral load of the father before sperm collection is > 75 copies / mL; 2. Mother or father has genetic variation within the target sequence of the CRISPR/Cas9 gene editing; 3. Mother or father has genetic variation, creating a novel, high-probability off-target site for CCR5-targeted gene editing; 4. During the study, natural pregnancy or fertilization failed after two oocyte stimulation cycles; 5. Previously multiple in vitro fertilization (IVF) attempts failed; 6. Contraindications to use drugs during pregnancy; 7. With endocrine-related diseases, sexual hormones are at abnormal levels; 8. Currently using chemoradiotherapy drugs to treat tumor-related diseases; 9. Participated in or recently participated in another clinical trial using a research diagnostic test, drug or device; 10. Subjects with other diseases, including alcohol abuse or mental illness, that may influence the current protocol based on the researcher or clinician's judgment.

Design outcomes

Primary

MeasureTime frame
Pregnancy and guarantee one or more live births;Father, mother and progeny genome-wide deep sequencing analysis;

Countries

China

Contacts

Public ContactHe Jiankui

Southern University of Science and Technology

hejk@sustc.edu.cn+86 18688955436

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026